ArQule Announces New Board Member, Michael D. Loberg.WOBURN, Mass. -- ArQule, Inc. (Nasdaq: ARQL) today announced that Michael D. Loberg, Ph.D., has been named to its board of directors. Dr. Loberg brings 27 years of senior management and drug development experience to ArQule, including leadership positions at NitroMed, Inc. and Bristol Myers Squibb Company. "Michael Loberg offers a strong combination of expertise in product development and commercialization in international markets," said Dr. Stephen A. Hill, president and chief executive officer of ArQule. "He is both a scientist and an entrepreneur who understands the field of oncology and the challenges faced by emerging biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. as therapeutic products move from research into clinical development and toward commercialization." Dr. Loberg served as president and chief executive officer of Nitromed from 2003 to 2006, and as chief executive officer of that company from 1997 to 2003. Previously, he served in a number of senior management positions at Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were (BMS BMS abbr. Bachelor of Marine Science ) from 1979 to 1997, including president of the Oncology and Immunology, U.S. Primary Care, Northern Europe, Specialty Pharmaceuticals and Squibb Diagnostics divisions. Dr. Loberg is also a director of Advanced Magnetics, Inc., Kereos and Inotek. He holds a B.S. in chemistry from Trinity College Trinity College, Ireland: see Dublin, Univ. of. Trinity College Private liberal arts college in Hartford, Conn., founded in 1823. It is historically affiliated with the Episcopal church, though its curriculum is nonsectarian. and a Ph.D. in chemistry from Washington University. About ArQule ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are designed to affect key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy(SM) (ACT). The Cancer Survival Protein modulation platform has generated a clinical-stage product designed to inhibit a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. and metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to . The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. For more information, please visit www.arqule.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion